Please check your internet connection and try again.
# Hyoscine butylbromide
## Overview
Hyoscine butylbromide (Scopolamine butylbromide) is a quaternary ammonium antispasmodic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier and lacks significant central nervous system effects. It acts by antagonizing muscarinic receptors in the smooth muscle of the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Symptomatic relief of gastrointestinal and urogenital tract spasms/cramps.
* Irritable Bowel Syndrome (IBS).
* Diagnostic aid in radiologic or endoscopic procedures (e.g., hypotonic duodenography).
* Palliative care: management of "death rattle" (respiratory tract secretions).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum daily dose: 80–100 mg.
* **Intramuscular/Intravenous:** 20 mg as a single dose; may be repeated every 30 minutes if necessary. Maximum daily dose: 100 mg.
* **Palliative Care:** 10–20 mg SC every 4 hours as needed, or 60–120 mg via continuous SC infusion over 24 hours.
## Pediatric Dosing
* **Children 6–12 years:** 10 mg orally three times daily.
* **Children over 12 years:** Same as adult dosing.
* *Note: Safety and efficacy in children under 6 years are not well established; use only under specialist guidance.*
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized dosing adjustments exist. Use with caution in patients with severe impairment; initiate at the lower end of the dosing range and monitor for accumulation of anticholinergic effects.
* **Elderly:** Use caution. Increased sensitivity to anticholinergic effects (e.g., urinary retention, constipation, tachycardia) necessitates lower starting doses.
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon or paralytic ileus.
* Untreated narrow-angle glaucoma.
* Tachycardia.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
* **Common:** Dry mouth, tachycardia, blurred vision (mydriasis), and constipation.
* **Serious:** Urinary retention, anaphylaxis/allergic reactions, and cardiovascular events (hypotension/tachycardia reported with IV administration).
## Key Drug Interactions
* **Anticholinergics:** Enhanced effect and increased risk of side effects (e.g., TCAs, antihistamines, antipsychotics).
* **Dopamine Antagonists:** May result in an antagonistic effect on gastrointestinal motility (e.g., metoclopramide).
* **Tachycardiac Agents:** Beta-agonists or sympathomimetics may exacerbate drug-induced tachycardia.
## Monitoring
* Monitor heart rate, especially with IV administration.
* Assess for resolution of spasmodic symptoms.
* Monitor for signs of urinary retention or ocular pressure issues in susceptible patients.
## Clinical Pearls
* **Parenteral Administration:** Rapid IV injection can cause a sudden, profound decrease in blood pressure and tachycardia; push slowly.
* **CNS profile:** Because it is a quaternary ammonium compound, it has minimal systemic distribution to the CNS, making it the preferred antispasmodic over atropine or scopalamine hydrobromide if CNS side effects must be avoided.
* **Effectiveness:** Evidence for efficacy in chronic conditions like IBS is inconsistent; consider short-term use only.
***
**Educational Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice. Dosing and protocols may vary based on institutional guidelines, country, and clinical context. Always consult current local drug monographs, such as the BNF or the product’s Summary of Product Characteristics (SmPC), before prescribing or administering medication.
